A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)

Authors of SAP: 

Version: 1.0
Version Date of SAP: 25 Sep 2018

Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, Massachusetts 02210-1862

CONFIDENTIAL
This document contains confidential information. Any use, distribution, or disclosure without the prior written consent of Vertex Pharmaceuticals Incorporated is strictly prohibited except to the extent required under applicable laws or regulations. Persons to whom the information is disclosed must be informed that the information is confidential and may not be further disclosed by them.
## TABLE OF CONTENTS

1 Title Page ................................................................................................................................. 1
2 Table of Contents .......................................................................................................................... 2
3 Modifications .................................................................................................................................... 4
   3.1 Modifications to the Approved Clinical Study Protocol .......................................................... 4
   3.2 Modifications to the Approved Statistical Analysis Plan ......................................................... 4
   3.3 Modifications to the Approved DMC Charter ......................................................................... 4
4 Introduction .................................................................................................................................. 5
5 Study Objectives .......................................................................................................................... 5
   5.1 Primary Objective ................................................................................................................... 5
   5.2 Secondary Objectives ............................................................................................................. 5
6 Study Endpoints ............................................................................................................................ 5
   6.1 Efficacy and Pharmacodynamic Endpoints ........................................................................... 5
      6.1.1 Primary Efficacy Endpoint ............................................................................................ 5
      6.1.2 Secondary Efficacy and Pharmacodynamic Endpoints .................................................. 5
   6.2 Safety Endpoints ................................................................................................................... 6
7 Study Design .................................................................................................................................. 6
   7.1 Overall Design ....................................................................................................................... 6
   7.2 Sample Size and Power .......................................................................................................... 7
   7.3 Randomization ....................................................................................................................... 7
   7.4 Blinding and Unblinding ........................................................................................................ 7
8 Analysis Sets .................................................................................................................................. 7
   8.1 All Subjects Set ...................................................................................................................... 8
   8.2 Full Analysis Set .................................................................................................................... 8
   8.3 Safety Set .................................................................................................................................. 8
9 Statistical Analysis ......................................................................................................................... 8
   9.1 General Considerations .......................................................................................................... 8
   9.2 Background Characteristics ................................................................................................... 9
      9.2.1 Subject Disposition ........................................................................................................... 9
      9.2.2 Demographics and Baseline Characteristics ................................................................... 10
      9.2.3 Medical History ............................................................................................................... 11
      9.2.4 Prior and Concomitant Medications .............................................................................. 11
      9.2.5 Study Drug Exposure ...................................................................................................... 12
      9.2.6 Study Drug Compliance .................................................................................................. 12
      9.2.7 Important Protocol Deviations ....................................................................................... 13
   9.3 Efficacy Analysis .................................................................................................................... 13
      9.3.1 Analysis of Primary Efficacy Variable ............................................................................. 13
      9.3.2 Analysis of Key Secondary Variables .......................................................................... 15
   9.4 Safety Analysis ....................................................................................................................... 17
### 9.4.1 Adverse Events

18

### 9.4.2 Clinical Laboratory

20

### 9.4.3 Electrocardiogram

20

### 9.4.4 Vital Signs

20

### 9.4.5 Pulse Oximetry

21

### 9.4.6 Physical Examination

21

### 9.4.7 Supportive Safety Analysis

21

### 10 Interim and DMC Analyses

22

#### 10.1 Interim Analysis

22

#### 10.2 DMC analysis

22

### 11 References

23

### 12 List of Appendices

24

- **Appendix A:** Analysis Visit Windows for Safety and Efficacy Assessment

- **Appendix B:** Imputation Rules for Missing Prior/Concomitant Medication Dates

- **Appendix C:** Details of GLI Equations for Calculating ppFEV\(_1\)

- **Appendix D:** Steps for Multiple Imputation

- **Appendix E:** Imputation Rules for Missing AE dates

- **Appendix F:** Criteria for Threshold Analysis

- **Appendix G:** Adverse Events of Special Interest

37
3  MODIFICATIONS

3.1  Modifications to the Approved Clinical Study Protocol
Not Applicable.

3.2  Modifications to the Approved Statistical Analysis Plan
This is the 1st version of Statistical Analysis Plan.

3.3  Modifications to the Approved DMC Charter
Not Applicable.
4 INTRODUCTION

This statistical analysis plan (SAP) is based on the most recent approved clinical study protocol (CSP), the most recent approved electronic case report form (eCRF), and the most recent approved eCRF completion guidelines.

This SAP (Methods) documents the planned final statistical analyses of efficacy and safety endpoints defined in the VX17-445-103 study protocol. It also documents analyses for additional efficacy and safety variables not specified in the protocol, which will provide supportive information for the scientific understanding of the drug entity.

The pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of VX-445/TEZ/IVA in the F508del homozygous population also will be evaluated in the study. Selected analyses related to sweat chloride will be documented in this SAP, other PK and PD analyses will be documented separately in the clinical pharmacology analysis plan (CPAP) for the study.

The Vertex Biometrics Department will perform the statistical analysis of the efficacy and safety data; SAS (Version 9.4 or higher) will be used to generate all statistical outputs (tables, figures, listings, and datasets). The SAP will be finalized and approved prior to the clinical database lock and treatment unblinding for the study. Any revisions to the approved SAP will be documented and approved in an amendment to the SAP prior to the clinical database lock for the final analysis. Any changes made to the SAP (Methods) after the clinical database lock has occurred will be documented in the clinical study report for this study.

5 STUDY OBJECTIVES

5.1 Primary Objective

To evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation (F/F)

5.2 Secondary Objectives

- To evaluate the safety of VX-445 in TC with TEZ and IVA
- To evaluate the PD of VX-445 in TC with TEZ and IVA
- To evaluate the PK of VX-445, TEZ, and IVA when administered in TC

6 STUDY ENDPOINTS

6.1 Efficacy and Pharmacodynamic Endpoints

6.1.1 Primary Efficacy Endpoint

Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV₁) from baseline at Week 4

6.1.2 Secondary Efficacy and Pharmacodynamic Endpoints

The key secondary efficacy endpoints are as follows:

- Absolute change in sweat chloride (SwCl) from baseline at Week 4
6.2 Safety Endpoints

Safety and tolerability will be evaluated via the following endpoints:

- Adverse events (AEs)
- Clinical laboratory values
- Standard 12-lead ECGs
- Vital signs
- Pulse oximetry

7 STUDY DESIGN

7.1 Overall Design

This is a Phase 3, randomized, double-blind, active-controlled, parallel-group, multicenter study. A schematic of the study design is shown in Figure 7-1.

In the TEZ/IVA Run-in Period, all subjects will receive TEZ 100 mg once daily (qd)/IVA 150 mg every 12 hours (q12h). Following completion of the TEZ/IVA Run-in Period, approximately 100 subjects will be randomized (1:1) to the TC arm or TEZ/IVA arm for the Treatment Period. The planned dosages for the Treatment Period are shown in Table 7-1.

<table>
<thead>
<tr>
<th>Treatment Arm</th>
<th>VX-445 Dosage</th>
<th>TEZ Dosage</th>
<th>IVA Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>VX-445/TEZ/IVA</td>
<td>200 mg qd</td>
<td>100 mg qd</td>
<td>150 mg q12h</td>
</tr>
<tr>
<td>TEZ/IVA</td>
<td>0 mg</td>
<td>100 mg qd</td>
<td>150 mg q12h</td>
</tr>
</tbody>
</table>

IVA: ivacaftor; q12h: every 12 hours; qd: once daily; TC: triple combination; TEZ: tezacaftor

All visits will occur within the windows specified. Please refer to the Table 3-1 and Table 3-2 of the CSP for more details about study visits and assessments.
Figure 7-1  Schematic of the Study Design

IVA: ivacaftor; N: number of subjects; TC: triple combination; TEZ: tezacaftor
Note: The Safety Follow-up Visit is not required for subjects who complete the Week 4 Visit and have enrolled in an open-label study within 28 days after the last dose of study drug (Section 9.1.4 of the CSP).

7.2  Sample Size and Power

The primary efficacy endpoint is the absolute change in ppFEV$_1$ from baseline at Week 4. The primary null hypothesis to be tested is that the mean absolute change in ppFEV$_1$ from baseline at Week 4 is the same for the TC and TEZ/IVA treatment groups. The null hypothesis will be tested at a 2-sided significance level of 0.05.

Assuming a within-group SD of 7 percentage points and a 5% dropout rate at Week 4, a sample size of 50 subjects in each treatment group for a total of 100 subjects will have approximately 93% power to detect a difference of 5.0 percentage points for the mean absolute change in ppFEV$_1$ from baseline at Week 4 between the 2 treatment groups, based on a 2-sided 2-sample t-test at a significance level of 0.05 using the

7.3  Randomization

Randomization will be stratified by ppFEV$_1$ determined during the TEZ/IVA Run-in Period (Day -14 assessment; <70 versus ≥70) and age at the Screening Visit (18 versus ≥18 years of age). If the Day -14 ppFEV$_1$ value is not valid or not available, the most recent available ppFEV$_1$ value before date of randomization will be used for stratification.

7.4  Blinding and Unblinding

Refer to the CSP Section 10.7 for details.

8  ANALYSIS SETS

The following analysis sets are defined: All Subjects Set, Full Analysis Set, Safety Set for the Run-in Period and Safety Set for the Treatment Period.

Vertex Pharmaceuticals Incorporated
8.1 All Subjects Set
The **All Subjects Set** will include all subjects who are randomized or receive at least 1 dose of study drug. This analysis set will be used for all individual subject data listings and disposition summary tables, unless otherwise specified.

8.2 Full Analysis Set
The **Full Analysis Set** (FAS) will include all randomized subjects who carry the intended CFTR allele mutation and receive at least 1 dose of study drug in the Treatment Period. The FAS will be used to summarize subject demographics and baseline characteristics, and for all efficacy analyses in which subjects will be analyzed according to their randomized treatment group, unless otherwise specified.

8.3 Safety Set
The **Safety Set for the Run-in Period** will include all subjects who receive at least 1 dose of TEZ/IVA in the Run-in Period. This safety set will be included in individual subject data listings, unless otherwise specified.

The **Safety Set for the Treatment Period** will include all subjects who receive at least 1 dose of study drug in the Treatment Period. This safety set will be used for all safety analyses in which subjects will be analyzed according to the treatment they receive, unless otherwise specified.

9 **STATISTICAL ANALYSIS**

9.1 General Considerations
The Schedule of Assessments is provided in Section 3 of CSP. The precision standards for reporting safety and efficacy variables are provided in an internal Biometrics document that specifies the programming rules including the precision for derived variables.

**Continuous variables** will be summarized using the following descriptive summary statistics: the number of subjects (n), mean, SD, median, minimum value (min), and maximum value (max).

**Categorical variables** will be summarized using counts and percentages. Percentages will be presented to 1 decimal place.

**Baseline value**, unless otherwise specified, is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the Treatment Period.

**Absolute change** from baseline will be calculated as post-baseline value – baseline value.

**Relative change** from baseline will be calculated as (post-baseline value – baseline value)/baseline value.

The **Treatment-emergent (TE) Period for the Run-in Period** will be from the first dose of study drug in the Run-in Period to

1) for subjects who complete the run-in period and continue to the Treatment Period, the first dose of study drug in the Treatment Period, or
2) for subjects who do not continue to the Treatment Period, either 28 days after the last dose date of study drug in the Run-in Period, or to the completion of study participation date, whichever occurs first.

The **TE Period for the Treatment Period** will include the time from the first dose date of study drug in the Treatment Period (TC or placebo + TEZ/IVA) to 28 days after the last dose of the study drug or to the completion of study participation date, whichever occurs first.

**Unscheduled visits:** Unscheduled visit measurements will be included in analysis as follows:

1) In scheduled visit windows per specified visit windowing rules
2) In the derivation of baseline and last on-treatment measurements
3) In the derivation of maximum and minimum values during TE period, and maximum and minimum change from baseline values during TE period for safety analyses
4) In individual subject data listings as appropriate

**Visit windowing rules:** The analysis visit windows for protocol-defined visits are provided in Appendix A.

**Incomplete/missing data** will not be imputed, unless specified otherwise.

**Outliers:** No formal statistical analyses will be performed to detect or remedy the presence of statistical outliers, unless specified otherwise.

**9.2 Background Characteristics**

**9.2.1 Subject Disposition**

A disposition table will be provided for the **Run-in Period** with the following categories:

- All Subjects Set
- Safety Set for the Run-in Period

The number and percentage (based on Safety Set for the Run-in Period) of subjects in each of the following disposition categories will be summarized:

- Prematurely discontinued treatment before randomization and the reason for treatment discontinuation
- Prematurely discontinued study before randomization and the reason for study discontinuation

A separate disposition table will be provided for the **Treatment Period** with the following categories:

- Full Analysis Set
- Safety Set for the Treatment Period
- Randomized
- Randomized but not dosed in the Treatment Period
- Randomized or dosed in the Treatment Period

Vertex Pharmaceuticals Incorporated
The number and percentage (based on FAS) of subjects in each of the following disposition categories will be summarized by treatment group and overall:

- Completed study drug treatment
- Prematurely discontinued treatment and the reason for discontinuation (i.e., discontinued all study drugs)
- Completed study
- Prematurely discontinued the study and the reason for discontinuation
- Rollover to the open-label study

A listing will be provided for subjects who discontinued treatment (including both the Run-in Period and Treatment Period) or who discontinued study with reasons for discontinuation.

9.2.2 **Demographics and Baseline Characteristics**

Demographics and baseline characteristics will be summarized based on the FAS, and presented by treatment group and overall, as applicable.

**Demographic data will include the following:**

- Age at baseline (in years)
- Sex (female and male)
- Ethnicity (Hispanic or Latino, not Hispanic or Latino, and not collected per local regulations)
- Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and not collected per local regulations)
- Geographic region (North America, Europe)

**Baseline characteristics will include the following:**

- Weight (kg)
- Height (cm)
- BMI (kg/m²)

**Stratification categories will include the following:**

- Age at Screening Visit (<18, ≥18 years)
- ppFEV₁ at Day -14 (<70, ≥70)

**Disease characteristics will include the following:**

- ppFEV₁ at baseline (<40, ≥ 40 to <70, ≥70 to ≤90, and >90)
- ppFEV₁ at baseline (continuous)
- Sweat chloride at baseline (continuous)
- CFQ-R respiratory domain score at baseline (continuous)
- Prior use of dornase alfa before first dose of study drug in the Treatment Period (Yes, No)
• Prior use of azithromycin before first dose of study drug in the Treatment Period (Yes, No)
• Prior use of inhaled antibiotic before first dose of study drug in the Treatment Period (Yes, No)
• Prior use of bronchodilator before first dose of study drug in the Treatment Period (Yes, No)
• Prior use of inhaled bronchodilator before first dose of study drug in the Treatment Period (Yes, No)
• Prior use of inhaled hypertonic saline before first dose of study drug in the Treatment Period (Yes, No)
• Prior use of inhaled corticosteroids before first dose of study drug in the Treatment Period (Yes, No)
• Infection with *Pseudomonas aeruginosa* within 2 years prior to screening (Positive, Negative)

In addition, data listings will also be provided for:

• Informed consent;
• Inclusion/Exclusion criteria violation for subjects with any such violations.

### 9.2.3 Medical History

Medical history will be coded by using the Medical Dictionary for Regulatory Activities (MedDRA). For the FAS, medical history will be summarized descriptively by system organ class and preferred term. The corresponding data listing will also be provided.

In addition, the number of subjects reported to have had positive cultures for respiratory pathogens within the 2 years prior to screening (i.e., answered yes on the respiratory microbiology form) will be summarized for the FAS. The corresponding data listing will be provided. Hospitalization and clinic visit history in the year prior to the signing of informed consent will be listed.

### 9.2.4 Prior and Concomitant Medications

Medications will be coded using the World Health Organization Drug Dictionary (WHO-DD) and categorized as follows:

**Prior medication:** any medication that was administered during the 56 days before the first dose of study drug in the Treatment Period but not in the Run-in Period. For subjects who discontinue during the Run-in Period and whose first dose of study drug in the Treatment Period is not available, prior medication will be any medication that was administered during the 56 days before the last dose of study drug in the Run-in Period but before the first dose in the Run-in Period.

**Concomitant medication during the Run-in Period:** medication continued or newly received during the TE period for the Run-in Period.

**Concomitant medication during the Treatment Period:** medication continued or newly received during the TE period for the Treatment Period.

**Post-treatment medication:** medication continued or newly received after:
• the TE period for the Run-in Period if the subject did not receive study drug in the Treatment Period.

• the TE period for the Treatment Period for subjects who received study drug in the Treatment Period.

A given medication may be classified as any combination of the above categories, for example, prior and concomitant during the Run-in Period, concomitant during the Treatment Period and post-treatment, or concomitant for both periods and post-treatment.

If a medication has completely missing or partially missing start/stop date and if it cannot be determined whether it was taken before the first dose date of study drug, concomitantly, or after the TE period, it will be classified as prior, concomitant for both periods, and post-treatment. Details for imputing missing or partial start and/or stop dates of medication are described in Appendix B.

Prior medications and concomitant medications will be summarized descriptively for FAS using frequency tables by: 1) treatment group and overall, preferred name (PN); and 2) treatment group and overall, anatomic class (ATC) level 1, ATC level 2, and PN.

Prior and concomitant medication during the Run-in Period will be summarized together in one summary table. Post-treatment medications will be listed in the all medication listing.

9.2.5 Study Drug Exposure

Study drug exposure will be summarized for the Treatment Period only based on the Safety Set for the Treatment Period, and will be presented by treatment group and overall.

Duration of study drug exposure (in days) will be calculated as: last dose date of study drug in the Treatment Period – first dose date of study drug in the Treatment Period + 1, regardless of study drug interruption, and will be summarized descriptively.

Study drug exposure (in weeks) will be summarized descriptively by the number of subjects (n), mean, SD, median, min, and max. It will also be summarized by interval: ≤2 weeks, >2- ≤4 weeks, and > 4 weeks, using counts and percentages. Additionally, the total study drug exposure, defined as the sum total of the study drug exposure across all subjects (in patient-weeks), will be provided.

9.2.6 Study Drug Compliance

Study drug compliance will be summarized for the Treatment Period only based on the FAS, and will be presented by treatment group and overall.

Study drug compliance will be calculated as: 100 × [1 - (total number of days of study drug interruption during the Treatment Period) / (duration of study drug exposure in days during the Treatment Period)]. A study drug interruption on a given day is defined as an interruption of any study drugs on that day. A study drug interruption that continues through the end of the study participation (i.e., subject does not resume study drug before the end of the study participation) will not be included in the compliance calculation.

Study drug compliance will be summarized descriptively by the number of subjects (n), mean, SD, median, min, and max. It will also be summarized in categories: <80% and ≥80% using frequency tables.
In addition, percentage of tablets taken will be calculated using the following formula:

\[
100 \times \left[ \frac{\text{(total number of tablets dispensed for the Treatment Period)} - \text{(total number of tablets returned for the Treatment Period)}}{\text{(total number of tablets planned to be taken per day}} \times \text{duration of study drug exposure in days for the Treatment Period).} \right]
\]

Summary similar to those for the study drug compliance will be produced based on the FAS.

9.2.7 Important Protocol Deviations

An important protocol deviation (IPD) is a deviation that may significantly affect the completeness, accuracy, or reliability of the study data or that may significantly affect a subject’s rights, safety, or well-being. IPD rules will be developed and finalized before database lock.

The protocol deviations that should be considered as potential IPDs include, but are not limited to:

- Subject was enrolled in the study despite the violation of inclusion/exclusion criteria
- Subject was less than 80% compliant with study drug for non-safety reasons
- Subject received prohibited concomitant medications
- Subject received the wrong treatment or incorrect doses
- Subject remained in the study despite meeting withdrawal criteria

Occurrence of any of these events should be considered as potential IPDs, but a blinded team should categorize them as IPDs only if they have the potential to significantly affect the completeness, accuracy, or reliability of the study data or that may significantly affect a subject’s rights, safety, or well-being.

IPDs (from the clinical database or from the site deviation log) will be summarized descriptively based on the FAS and presented by treatment group and overall. Additionally, IPDs will be provided in an individual subject data listing.

9.3 Efficacy Analysis

Unless otherwise defined, all efficacy analyses described in this section will be based on the FAS.

9.3.1 Analysis of Primary Efficacy Variable

9.3.1.1 Definition of Variable

The primary efficacy variable is the absolute change in ppFEV\(_1\) from baseline at Week 4. Percent predicted FEV\(_1\) is the ratio of FEV\(_1\) (L) to the predicted FEV\(_1\) (L), expressed as a percentage. The predicted FEV\(_1\) will be calculated using the Global Lung Function Initiative (GLI); details are in Appendix C.

9.3.1.2 Primary Analysis

The primary analysis will be performed using a mixed-effects model for repeated measures (MMRM) with the absolute change from baseline at Day 15 and Week 4 as the dependent variable. The model will include treatment group, visit, and treatment-by-visit interaction as fixed effects, with continuous baseline ppFEV\(_1\), and age at screening (<18 versus ≥18 years of age) as covariates. The model will be estimated using restricted maximum likelihood.
Denominator degrees of freedom for the $F$-test for fixed effects will be estimated using the Kenward-Roger approximation$^2$. An unstructured covariance structure will be used to model the within-subject errors. If the model estimation does not converge, a compound symmetry covariance structure will be used instead. Conditional on the observed data and covariates, missing data will be assumed to be missing at random; consequently, no imputation of missing data will be performed.

The primary result obtained from the model will be the estimated treatment difference at Week 4. The adjusted means with 2-sided 95% confidence intervals and 2-sided $P$ values will be provided. Furthermore, the treatment difference at each post-baseline visit obtained from the model will also be provided.

The adjusted mean (with SE) obtained from the MMRM analysis at each post-baseline visit up to Week 4 will be plotted by treatment group.

### 9.3.1.3 Supportive Analysis

There will be no supportive analysis for the primary efficacy endpoint.

### 9.3.1.4 Sensitivity Analysis

**MMRM based on Multiple Imputation (MI)**

An underlying assumption of the MMRM method is that data are missing at random. To minimize the amount of missing data, subjects who prematurely discontinue study drug treatment will continue to complete all scheduled study visits for spirometry and other efficacy assessments.

To assess the impact of missing data and the assumption that data are missing at random, a multiple imputation algorithm will be used if at least 10% of the subjects have missing changes in ppFEV$_1$ at Week 4 in any treatment group. Missing absolute change from baseline in ppFEV$_1$ assessments will be imputed starting from the first visit with missing values, for which all subsequent visits through Week 4 are also missing. For intermediate missing data, i.e., missing values that fall between two non-missing ones, it is reasonable to assume that they are missing at random and therefore will not be imputed. An MMRM analogous to that for the primary analysis of the primary endpoint will be applied to each imputed dataset and the relevant MI estimators will be reported. Details for the MI steps are presented in Appendix D.

### 9.3.1.5 Subgroup Analysis

Subgroup analyses of the primary efficacy endpoint will be performed using a model similar to that of the primary analysis for each of the following subgroups. The primary result obtained from the model will be the treatment effect at Week 4:

- Age at Screening (<18, ≥18 years)
- ppFEV$_1$ at baseline (< 70, ≥ 70)
- Sex (male, female)
- Geographic region (North America, Europe)
- Prior use of inhaled antibiotic before the first of study drug in the Treatment Period (Yes, No)
• Prior use of dornase alfa before the first of study drug in the Treatment Period (Yes, No)
• Prior use of inhaled bronchodilator before the first of study drug in the Treatment Period (Yes, No)
• Prior use of inhaled hypertonic saline before the first of study drug in the Treatment Period (Yes, No)
• Prior use of inhaled corticosteroids before the first of study drug in the Treatment Period (Yes, No)
• Prior use of azithromycin before the first of study drug in the Treatment Period (Yes, No)
• Infection with *Pseudomonas aeruginosa* within 2 years prior to screening (Positive, Negative)

The MMRM used for the primary analysis will be used for the subgroup analysis, where the same model will be applied to each category of the subgroup. Note that for the subgroup analysis based on age, the covariate of age at screening (<18 versus ≥18 years) from the MMRM will be removed. The adjusted means with 2-sided 95% confidence intervals will be provided. Furthermore, the estimated treatment difference at Week 4 in different categories within a subgroup will also be presented in a forest plot. Note: The results from the subgroup analysis should be interpreted with caution in the cases where sample sizes are small.

### 9.3.2 Analysis of Key Secondary Variables

#### 9.3.2.1 Definition of Variables

**Sweat chloride (SwCl):** The SwCl value for a given visit will be calculated as the mean of the non-missing sweat chloride measurements obtained on the left and right arms at that visit. If one of the two arm measurements at a time point is missing, the other will be used as the mean. A volume ≥15 μL is required for an accurate determination of sweat chloride. Any results reported as having volume <15 μL will be considered missing. Any sweat chloride values reported as <10 mmol/L or >160 mmol/L will be considered missing.

**Cystic Fibrosis Questionnaire-Revised (CFQ-R):** The CFQ-R is a validated CF-specific instrument that measures quality-of-life domains. This study utilizes three different versions of CFQ-R:

• CFQ-R for Children ages 12 and 13
• CFQ-R for Adolescents and Adults (subjects 14 years and older)
• CFQ-R for Parents/Caregivers (subjects 13 years and younger)

In all three versions, specific question belonging to a domain is scored 1, 2, 3, or 4. The CFQ-R domain score, e.g., physical domain score or respiratory domain score, is defined as a scaled score as follows:

\[
\text{Scaled score for a domain} = 100 \times (\text{mean (scores of all questions in the domain)} - 1)/3,
\]

where the score from a negatively phrased question is first reversed, i.e., reversed score = 5 – actual score, so that 1 always represents the worst condition and 4 the best condition. The (scaled) domain score ranges from 0 (worst condition) to 100 (best condition). The scaled score
for a specific domain will not be calculated if more than half of the questions in the domain have missing scores.

The (scaled) domain score from the CFQ-R for Children ages 12 and 13 and for Adolescent and Adults will be pooled for the analysis purpose.

9.3.2.2 Analysis Method

Absolute change in SwCl from baseline at Week 4:

Analysis of absolute change from baseline in sweat chloride will be based on an MMRM similar to the primary analysis of the primary efficacy variable. The model will include treatment, visit, and treatment-by-visit interaction as fixed effects with continuous baseline ppFEV$_1$, and age at screening (<18 versus ≥18 years of age) as covariates.

Absolute change in CFQ-R respiratory domain score from baseline at Week 4:

Analysis of absolute change from baseline in CFQ-R respiratory domain score will be based on an MMRM similar to the primary analysis of the primary efficacy variable. The model will include treatment, visit, and treatment-by-visit interaction as fixed effects with continuous baseline ppFEV$_1$, and age at screening (<18 versus ≥18 years of age) as covariates.

The LS mean (SE) of the within-treatment group change from baseline at each post-baseline visit up to Week 4 along with the 95% CI will be estimated from the corresponding MMRM. The LS mean (SE) of the treatment difference between VX-445/TEZ/IVA and TEZ/IVA at each post-baseline visit will be provided along with the corresponding 95% CI and P value. The LS mean (SE) at each visit will also be plotted by treatment group. In addition, the post-baseline raw values and the absolute change from baseline at each post-baseline visit up to Week 4 will be summarized descriptively (n, mean, SD, median, minimum, and maximum).

9.3.2.3 Multiplicity Adjustment

The key secondary endpoints will be formally tested at an alpha of 0.05 only if the primary endpoint is statistically significant. A hierarchical testing procedure will be used to control the type I error rate for the multiple key secondary endpoints tested at an alpha of 0.05. For a test at any step to be considered statistically significant within the testing hierarchy, it must be statistically significant, and all previous tests (if any) within the hierarchy must be statistically significant at the 0.05 level. The testing order of the key secondary endpoints is as follows:

- Absolute change in SwCl from baseline at Week 4
- Absolute change in CFQ-R respiratory domain score from baseline at Week 4
9.4 Safety Analysis

All safety analyses will be based on data from the TE period for the Treatment Period for all subjects in the corresponding Safety Set for the Treatment Period, unless otherwise specified. Subjects will be analyzed according to the treatment they actually received in the Treatment Period. For subjects receiving study drug from more than one treatment group, the treatment group allocation will be the higher treatment group (VX-445/TEZ/IVA > TEZ/IVA).

The overall safety profile of study drug will be assessed in terms of the following safety and tolerability endpoints:

- Treatment-emergent adverse events (TEAEs)
- Clinical laboratory values
- ECGs
- Vital signs
- Pulse oximetry
Only descriptive analysis of safety will be performed and no statistical testing will be performed. The safety data during the Run-in Period will only be presented in listings, unless otherwise specified.

### 9.4.1 Adverse Events

For analysis purposes, AEs will be classified as pretreatment AEs, TEAEs during the Run-in Period, TEAEs during the Treatment Period, and post-treatment AEs, defined as follows:

**Pretreatment AE:** any AE that occurred before the first dose date of study drug (TEZ/IVA) in the Run-in Period

**TEAE during the Run-in Period:** any AE that worsened (either in severity or seriousness) or that was newly developed at or after the first dose date of study drug (TEZ/IVA) through the end of the TE period for the Run-in Period

**TEAE during the Treatment Period:** any AE that worsened (either in severity or seriousness) or that was newly developed at or after the first dose date of study drug (TC or placebo+TEZ/IVA) through the end of the TE period for the Treatment Period

**Post-treatment AE:** any AE that worsened (either in severity or seriousness) or that was newly developed after:

- the TE period for Run-in Period if the subject did not receive treatment in the Treatment Period
- the TE period for the Treatment Period if the subject received treatment in the Treatment Period

For AEs with completely missing or partially missing start dates, if there is no clear evidence that the AEs are pre-treatment or TEAE during the Run-in Period or post-treatment, the AEs will be classified as TEAEs corresponding to the Treatment Period. Unless otherwise specified, TEAE refers to TEAE during the Treatment Period.

Details for imputing missing or partial start dates of adverse events are described in Appendix E. An overview of all TEAEs by treatment group and overall will be summarized in the following categories:

- Number of TEAEs (total number of TEAEs only)
- Subjects with any TEAEs
- Subjects with TEAEs by strongest relationship
- Subjects with TEAEs by maximum severity
- Subjects with TEAEs leading to study drug discontinuation (discontinuation of any study drugs)
- Subjects with TEAEs leading to study drug interruption (interruption of any study drugs)
- Subjects with Grade 3/4 TEAEs
- Subjects with related TEAEs
- Subjects with serious TEAEs

Vertex Pharmaceuticals Incorporated
• Subjects with related serious TEAEs
• Subjects with TEAE leading to death

The following summary tables of TEAEs will be presented by treatment group:

• All TEAEs
• Grade 3/4 TEAEs
• TEAEs by strongest relationship
• TEAEs by maximum severity
• TEAEs leading to treatment discontinuation
• TEAEs leading to treatment interruption
• Related TEAEs
• Serious TEAEs
• Related serious TEAEs
• TEAEs leading to death

Summaries will be presented by MedDRA System Organ Class (SOC) and Preferred Term (PT) using frequency counts and percentages (i.e., number and percentage of subjects with an event). When summarizing the number and percentages of subjects, subjects with multiple occurrences of the same adverse event or a continuing adverse event will be counted once, and only the maximum severity level will be presented in the severity summaries, and the strongest relationship level in the relationship summaries.

Additional summary tables will be presented by treatment group for TEAEs showing number and percentage of subjects

• All TEAEs by PT

All AEs, including pretreatment AEs, TEAEs for all applicable periods, and post-treatment AEs, will be presented in an individual subject data listing based on the All Subjects Set. In addition, separate listings containing individual subject adverse event data for TEAEs leading to treatment discontinuation, TEAEs leading to treatment interruption, Grade 3/4 TEAEs, SAEs and all deaths will be provided separately, with a flag indicating the TEAE status for SAEs and deaths.

In addition, the following tables for the Run-in period will be presented by overall based on the Safety Set for the Run-in period.

• An overview of TEAEs during the Run-in Period
• All TEAEs during the Run-in Period by SOC and PT

9.4.1.1 Subgroup Analysis

An overview of all TEAEs and a summary of TEAEs by SOC and PT for the following subgroups will be provided:

• Age at screening (<18, ≥18 years)
• ppFEV$_1$ at baseline (<70, ≥70)
• Sex (male, female)
• Geographic region (North America, Europe)

### 9.4.2 Clinical Laboratory

For the treatment-emergent laboratory assessments, the observed values and change from baseline values of the continuous hematology, coagulation and chemistry results will be summarized in SI units at each visit by treatment group.

The number and percentage of subjects meeting at least 1 threshold analysis criterion event, during the TE period for Treatment Period, will be summarized by treatment group. The threshold analysis criterion shift from baseline will also be summarized for selected laboratory parameters. The threshold analysis criteria are provided in Appendix F.

For selected LFT laboratory test (alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase [ALP], and total bilirubin), a scatter plot of the maximum treatment-emergent value versus the baseline value corresponding to ×ULN (upper limit of normal) will be presented. Further, a scatter plot of the maximum treatment-emergent value of ALT and AST, separately, versus the maximum treatment-emergent value of total bilirubin corresponding to ×ULN will also be presented by treatment group.

Results of urinalysis and positive urine/serum pregnancy test will be listed in individual subject data listings only. For positive serum pregnancy listing, subjects with serum HCG which are abnormally high will be selected.

In addition, a listing containing individual subject hematology, chemistry, and coagulation values will be provided. This listing will include data from both scheduled and unscheduled visits.

### 9.4.3 Electrocardiogram

For the treatment-emergent ECG measurements, a summary of observed values and change from baseline values will be provided at each visit by treatment group for the following ECG interval measurements (in msec): RR interval, PR interval, QT interval, QTcF interval, QRS duration, and Heart Rate (beats per minute).

The number and percentage of subjects meeting at least 1 threshold analysis criterion during the TE period for the Treatment Period will be summarized by treatment group. The threshold analysis criteria are provided in Appendix F.

In addition, a listing containing individual subject ECG values will be provided. This listing will include data from both scheduled and unscheduled visits.

### 9.4.4 Vital Signs

For the treatment-emergent vital signs measurements, the observed values and change from baseline values will be summarized at each visit by treatment group. The following vital signs parameters will be summarized: BMI (kg/m$^2$), weight (kg), height (cm), systolic and diastolic blood pressure (mm Hg), body temperature (°C), pulse rate (beats per minute), and respiratory rate (breaths per minute).
The number and percentage of subjects meeting at least 1 threshold analysis criterion during the TE period for the Treatment Period will be summarized by treatment group. The threshold analysis criteria are provided in Appendix F.

In addition, a listing containing individual subject vital signs values will be provided. This listing will include data from both scheduled and unscheduled visits.

9.4.5 Pulse Oximetry

For the treatment-emergent oxygen saturation values by pulse oximetry, a summary of observed values and change from baseline values will be provided at each visit by treatment group.

The number and percentage of subjects with shift changes from baseline (normal/missing and low according to the reference range) to the lowest percent of oxygen saturation during the TE period for the Treatment Period will be summarized by treatment group.

9.4.6 Physical Examination

Abnormal PE findings will be presented as an individual subject data listing only.

9.4.7 Supportive Safety Analysis

9.4.7.1 Adverse Events of Special Interest

For this study, elevated transaminase events and rash events, as determined by MedDRA preferred terms in Appendix G, are considered as adverse events of special interest.

For treatment-emergent elevated transaminase events and rash events, the following categories will be summarized by treatment group:

- Subjects with events
- Subjects with events by maximum severity
- Subjects with events leading to treatment discontinuation
- Subjects with events leading to treatment interruption
- Subjects with serious events
- Subjects with related serious events
- Subjects with events leading to death
- Duration of events
- Time-to-onset of first event

In addition, for treatment-emergent rash events, these categories will be summarized for the following subgroups:

- Sex (male, female)
- Female subjects with concomitant hormonal therapy (Yes, No)
9.4.7.2 Hormonal Therapy
The number of subjects who used hormonal therapy concomitantly will be summarized by
treatment group based on the Safety Set for the Treatment Period.

10 Interim and DMC Analyses
10.1 Interim Analysis
No formal interim analysis is planned.
10.2 DMC analysis
The DMC’s objectives and operational details are defined in a separate document (DMC
Charter) which was finalized before the first subject was screened in the study. The DMC’s
planned safety reviews of study data are outlined in the DMC Charter and DMC Statistical
Analysis Plan.
11 REFERENCES


## 12 LIST OF APPENDICES

**Appendix A: Analysis Visit Windows for Safety and Efficacy Assessment**

**Table 12-1 Analysis Visit Windows for Safety and Efficacy Assessments**

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Visit</th>
<th>Target Study Day</th>
<th>Analysis Visit Window (in study days)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety Assessment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Chemistry (Hematology)</td>
<td>Day 1</td>
<td>1</td>
<td>≤1 Pre-dose</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>15</td>
<td>[1, 22]</td>
</tr>
<tr>
<td></td>
<td>Week 4</td>
<td>29</td>
<td>(22, 43) Use nominal visit</td>
</tr>
<tr>
<td></td>
<td>Safety Follow-up</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Standard 12-lead ECG</td>
<td>Day 1</td>
<td>1</td>
<td>≤1 Pre-dose</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>Not applicable</td>
<td>Use nominal visit</td>
</tr>
<tr>
<td></td>
<td>Week 4</td>
<td>29</td>
<td>(22, 43) Use nominal visit</td>
</tr>
<tr>
<td></td>
<td>Safety Follow-up</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>Coagulation</td>
<td>Day 1</td>
<td>1</td>
<td>≤1 Pre-dose</td>
</tr>
<tr>
<td></td>
<td>Week 4</td>
<td>29</td>
<td>[1, 43] Use nominal visit</td>
</tr>
<tr>
<td></td>
<td>Safety Follow-up</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td><strong>Vital Signs (excluding BMI, Weight, Height and their Z-scores)</strong></td>
<td>Day 1</td>
<td>1</td>
<td>≤1</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>15</td>
<td>[1, 22]</td>
</tr>
<tr>
<td></td>
<td>Week 4</td>
<td>29</td>
<td>(22, 43) Use nominal visit</td>
</tr>
<tr>
<td></td>
<td>Safety Follow-up</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td><strong>Efficacy Assessment and Pharmacodynamic Assessment</strong></td>
<td>Day 1</td>
<td>1</td>
<td>≤1 Pre-dose</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>15</td>
<td>(1, 22)</td>
</tr>
<tr>
<td></td>
<td>Week 4</td>
<td>29</td>
<td>(22, 43) &gt;43</td>
</tr>
<tr>
<td></td>
<td>Safety Follow-up</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td><strong>Spirometry</strong></td>
<td>Day 1</td>
<td>1</td>
<td>≤1 Pre-dose</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>15</td>
<td>(1, 22)</td>
</tr>
<tr>
<td></td>
<td>Week 4</td>
<td>29</td>
<td>(22, 43) &gt;43</td>
</tr>
<tr>
<td></td>
<td>Safety Follow-up</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td><strong>Sweat Chloride</strong></td>
<td>Day 1</td>
<td>1</td>
<td>≤1 Pre-dose</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>15</td>
<td>(1, 22)</td>
</tr>
<tr>
<td></td>
<td>Week 4</td>
<td>29</td>
<td>(22, 43) &gt;43</td>
</tr>
<tr>
<td></td>
<td>Safety Follow-up</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td><strong>CFQ-R, Weight, Height and BMI</strong></td>
<td>Day 1</td>
<td>1</td>
<td>≤1</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>15</td>
<td>(1, 22)</td>
</tr>
<tr>
<td></td>
<td>Week 4</td>
<td>29</td>
<td>(22, 43) &gt;43</td>
</tr>
<tr>
<td></td>
<td>Safety Follow-up</td>
<td>Not applicable</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
1. Visit name for analysis purpose is used to report data in tables and figures.

2. The analysis visit windows will be applied using the following rules for both scheduled and unscheduled visits:
   a. If no numerical measurement is available within a visit window, the measurement will be considered missing for the visit.
   b. If there is more than 1 numerical measurement available within a visit window, use the following rules:
      i. The measurement closest to the target day will be used; or
      ii. If there are multiple measurements with the same distance from the target day, the latest measurement will be used.
**Table 12-1  Analysis Visit Windows for Safety and Efficacy Assessments**

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Visit</th>
<th>Target Study Day</th>
<th>Analysis Visit Window</th>
</tr>
</thead>
</table>

1. **Visit** (in study days)

4. **For lab, ECG and vital sign measurement collected on the date of first dose of study drug in Treatment Period, if it cannot be determined whether the measurement is before or after the first dose:**
   a. Scheduled measurement will be treated as pre-dose observation.
   b. Unscheduled measurement will be treated as post-dose observation.

4. **For safety assessment, Safety Follow-up analysis visit will be based on nominal Safety Follow-up visit. If a subject doesn’t have a nominal Safety Follow-up visit but has an ETT visit with study day >43, then the ETT visit will be mapped into Safety Follow-up analysis visit.**

**Derived Variables:**

1. **Age (in years) at first dose date and nominal visit** (for demographics, listing and the calculation of [percent] predicted spirometry variables):
   - Obtain the age at informed consent (in days) in “yy, mm” format (e.g., 24 years, 6 months) from the Vital Signs (VS) page at the Screening Visit, and add 0.5 month to convert to days.
   - Obtain the informed consent date.
   - Then age (in years) at first dose or nominal visit = [(first dose date or nominal visit date – informed consent date) in days + age at informed consent (in days)]/365.25.

2. **Age (in months) at nominal visit** (for use in calculation of BMI and weight z-score):
   - Obtain the age at informed consent (in months) in “yy, mm” format (e.g., 24 years, 6 months) from Vital Signs (VS) page at the Screening Visit.
   - Obtain the informed consent date.
   - Then age (in months) at nominal visit = integer part of {[(age at informed consent (in months) + 0.5 + diff(first dose date or nominal visit date, informed consent date) in months]} + 0.5.

3. **Missing first dose date or last dose date**
   - If the first dose date is missing, use Day 1 visit date to impute.
   - If the last dose date is missing or partial date is reported, the last dose date will be imputed based on, in descending order priority, the Early Treatment Termination (ETT) visit date, last visit date before the Safety Follow-up, or the last study drug administration date from EX SDTM domain, as appropriate. The imputation algorithm will ensure the imputed last dose date does not exceed the study participation end date.

4. **Sweat Chloride:**
   - Non-missing sweat chloride concentrations from the left arm and right arm with assessment end date/time for a given arm up to 30 minutes after first dose time in treatment period will be considered for baseline.

5. **Electrocardiogram:**
   - Baseline is defined as the most recent pretreatment measurement before the first dose of study drug in the Treatment Period. If multiple ECG measurements are obtained on the same calendar day during the TE period,
     - For summary purpose, the calculated average ECG will be used as the ECG value on that day (except for Day 15 visit);
     - For threshold analysis purpose, all reported ECG values will be used.
Appendix B: Imputation Rules for Missing Prior/Concomitant Medication Dates

Imputation rules for missing or partial medication start/stop dates are defined below:

1. Missing or partial medication start date:
   a. If only DAY is missing, use the first day of the month.
   b. If DAY and Month are both missing, use the first day of the year.
   c. If DAY, Month and Year are all missing, use a date before the first dose date (in practical, use Jan. 01, 2000 to impute).

2. Missing or partial medication stop date:
   a. If only DAY is missing, use the last day of the month.
   b. If DAY and Month are both missing, use the last day of the year.
   c. If DAY, Month and year are all missing, assign ‘continuing’ status to stop date (in practical, use Dec. 31, 2050 to impute).

In summary, the prior, concomitant, or post categorization of a medication is described below.

<table>
<thead>
<tr>
<th>Medication Start Date</th>
<th>Medication Stop Date</th>
<th>&lt; First Dose Date of Run-in TE Period</th>
<th>≥ First Dose Date and &lt; End Date of Run-in TE Period</th>
<th>≥ First Dose Date and ≤ End Date of Treatment TE Period</th>
<th>&gt; End Date of Treatment TE Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; First dose date of Run-in TE period</td>
<td>P</td>
<td>PC1</td>
<td>PC1C2</td>
<td>PC1C2A</td>
<td></td>
</tr>
<tr>
<td>≥ First dose date and &lt; End date of Run-in TE Period</td>
<td>-</td>
<td>C1</td>
<td>C1C2</td>
<td>C1C2A</td>
<td></td>
</tr>
<tr>
<td>≥ First dose date and ≤ End date of Treatment TE Period</td>
<td>-</td>
<td>-</td>
<td>C2</td>
<td>C2A</td>
<td></td>
</tr>
<tr>
<td>&gt; End date of Treatment TE Period</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>A</td>
<td></td>
</tr>
</tbody>
</table>

P: Prior; C1: Concomitant during the Run-in Period; C2: Concomitant during the Treatment Period; A: Post

Imputation rules for missing and/or partial dates of non-pharmacological treatment/procedure will follow the same imputation rule.
Appendix C: Details of GLI Equations for Calculating ppFEV$_1$

Percent predicted values will be calculated for parameters of FEV$_1$, using the Quanjer GLI-2012 Regression Equations and Lookup Tables.

The regression equations and lookup tables required to implement the Quanjer GLI-2012 predicted values are available in:


The instructions and tools on how to implement the Quanjer GLI-2012 equations are:


Data handling rule for spirometry is as follows:

- Input age with at least 2 decimal place
- Use height at screening regardless if height is collected at other study visits for subjects whose age at informed consent is >21 years. For subjects with age <=21 years, height collected at the respective visit should be used; if the height at the respective visit is not available, the last non-missing record will be used.
- For race, map the CRF reported Black or African American to Black, all other races in CRF (except White) are mapped to 'other'; multiple checks for race in CRF are also mapped to 'other'; white is a reference race in the equations and assumes 0 values for all race coefficients in the GLI equations.
Appendix D: Steps for Multiple Imputation

For the multiple imputation (MI) to be applied to the MMRM model for the primary efficacy endpoint, the following steps will be followed:

Imputation distribution

The imputation distribution for the missing absolute change from baseline in ppFEV$_1$ at visit $t$ will be a normal distribution. All randomized subjects will be classified into one of three categories based on the following rules:

- Non-missing category: Subjects who have a ppFEV$_1$ assessment at Week 4 (i.e., subjects who have a non-missing absolute change from baseline in ppFEV$_1$ at Week 4).
- Missing category 1: Subjects with missing absolute change from baseline in ppFEV$_1$ at Week 4, who discontinued treatment because of adverse events, noncompliance with study drug, death, or physician decision, or because the subject refused further dosing or required prohibited medication.
- Missing category 2: Subjects who discontinued treatment for any reason not listed in Category 1 and have missing absolute change from baseline in ppFEV$_1$ at Week 4, or subjects who have completed 4 weeks treatment duration but are missing the absolute change from baseline in ppFEV$_1$ at visit Week 4.

Imputation algorithm

We will use the following algorithm that relates the mean of the missing absolute change from baseline in ppFEV$_1$ at visit $t$ to the missing categories defined above. The algorithm will be implemented within each treatment group as follows:

- Missing category 1: randomly draw a sample from the normal distribution($\mu_{25}, \sigma^2$), where $\mu_{25}$ is the 25th percentile of the non-missing absolute changes from baseline in ppFEV$_1$ at visit $t$ and $\sigma^2$ is the sample variance estimated using the non-missing absolute changes at visit $t$.
- Missing category 2: randomly draw a sample from the normal distribution($\mu, \sigma^2$), where $\mu$ is the mean of the non-missing absolute changes from baseline in ppFEV$_1$ at visit $t$ and $\sigma^2$ is the sample variance estimated using the non-missing absolute changes at visit $t$.

Analysis model

The complete MI method is described below:

- Form an “imputed dataset” by imputing missing values at each visit for those subjects who have a missing value at the visit and have all subsequent values missing. The appropriate normal distribution specified in the algorithm above will be used for each such subject, based on their category.
- Repeat this process $K$ ($K=20$) times to form $K$ imputed datasets.
- Fit the same MMRM model to each imputed dataset to estimate the absolute change at Week 4.
- Combine the results from the $K$ imputed datasets using the SAS procedure MIANALYZE to derive the MI estimator.
Let $\theta$ be the true treatment difference. Denote by $\tilde{\theta}_k$ the estimate of $\theta$ from the $k^{th}$ imputed dataset, and the corresponding estimate of the variance is denoted by $V_k$. The MI estimator of $\theta$, $\tilde{\theta}_{MI}$, is the average of the $K$ individual estimates.

The estimated variance of $\tilde{\theta}_{MI}$ is a combination of the between- and within-imputation variability as follows: $V_{MI} = W + \left(1 + \frac{1}{K}\right)B$, where $W = \frac{1}{K} \sum_{k=1}^{K} V_k$ is the within-imputation variability and is $B = \frac{1}{K-1} \sum_{k=1}^{K}(\tilde{\theta}_k - \tilde{\theta}_{MI})^2$ is the between-imputation variance. The statistic $t = \frac{\tilde{\theta}_{MI} - \theta}{\sqrt{V_{MI}}}$ has an approximate $t_\nu$ distribution, where $\nu = (K - 1)(1 + \frac{W}{B})^2$. 
Appendix E: Imputation Rules for Missing AE dates

Imputation rules for missing or partial AE start date are defined below. If the imputed AE start date is before the informed consent date, the AE start date will be imputed using the study informed consent date.

- **If only Day of AE start date is missing:**
  - If the full (or partial) AE end date is NOT before the first dose date of the Treatment Period or AE end date is missing, then
    - if AE start year and month are equal to the month and year of first dose date of the Treatment Period, then impute the AE start day as the day of first dose date of the Treatment Period;
    - else if AE start year and month are equal to the month and year of first dose date of the Run-in Period, then impute the AE start day as the day of first dose date of the Run-in Period;
    - else impute the AE start day as 1.
  - else if the full (or partial) AE end date is NOT before the first dose date of the Run-in Period, then
    - if AE start year is equal to the year of first dose date of the Run-in Period, then impute the AE start month and day as the month and day of first dose date of the Run-in Period;
    - else impute the AE start day as 1.
  - else impute the AE start day as 1.

Compare the imputed AE start date with TE period to determine whether the AE is pretreatment AE, TEAE during the Run-in Period, TEAE during the Treatment Period, or post-treatment AE.

- **If Day and Month of AE start date are missing:**
  - If the full (or partial) AE end date is NOT before the first dose date of the Treatment Period or AE end date is missing, then
    - if AE start year is equal to the year of first dose date of the Treatment Period, then impute the AE start month and day as the month and day of first dose date of the Treatment Period;
    - else if AE start year is equal to the year of first dose date of the Run-in Period, then impute the AE start month and day as the month and day of first dose date of the Run-in Period;
    - else impute the AE start month as January and day as 1.
  - else if the full (or partial) AE end date is NOT before the first dose date of the Run-in Period, then
    - if AE start year is equal to the year of first dose date of the Run-in Period, then impute the AE start month and day as the month and day of first dose date of the Run-in Period;
- else impute the AE start month as January and day as 1.
  - else impute the AE start month as January and day as 1.

Compare the imputed AE start date with TE period to determine whether the AE is pretreatment AE, TEAE during the Run-in Period, TEAE during the Treatment Period, or post-treatment AE.

- If Year of AE start date is missing:
  
  If the year of AE start is missing or AE start date is completely missing then query site and
  - If the full (or partial) AE end date is NOT before the first dose date of the Treatment Period or AE end date is missing, then impute the AE start date as the date of first dose date of the Treatment Period.
  - else if the full (or partial) AE end date is NOT before the first dose date of the Run-in Period, then impute the AE start date as the date of first dose date of the Run-in Period.
  - else impute AE date as the informed consent date.

The imputation should ensure the imputed AE start date is not before the informed consent date.

Imputation rules for partial AE end date are defined below:

If partial end date, then impute as min (the last day of the month, end of study participation) if day is missing, or min (Dec, end of study participation) if month is missing.
## Appendix F: Criteria for Threshold Analysis

### Table 12-3  
**Threshold Analysis Criteria for Laboratory Tests (as applicable)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Threshold Analysis</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Chemistry (LFT)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td>&gt;ULN - ≤3xULN</td>
<td>FDA DILI Guidance Jul 2009.</td>
</tr>
<tr>
<td></td>
<td>&gt;3x - ≤5xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;5x - ≤8xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;8x - ≤20.0xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;20.0xULN</td>
<td></td>
</tr>
<tr>
<td>AST</td>
<td>&gt;ULN - ≤3xULN</td>
<td>FDA DILI Guidance Jul 2009.</td>
</tr>
<tr>
<td></td>
<td>&gt;3x - ≤5xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;5x - ≤8xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;8x - ≤20.0xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;20.0xULN</td>
<td></td>
</tr>
<tr>
<td>ALT or AST</td>
<td>(ALT&gt;ULN - ≤ 3xULN) or (AST&gt;ULN - ≤ 3xULN)</td>
<td>FDA DILI Guidance</td>
</tr>
<tr>
<td></td>
<td>(ALT&gt;3x - ≤ 5xULN) or (AST&gt;3x - ≤ 5xULN)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(ALT&gt;5x- ≤ 8xULN) or (AST&gt;5x - ≤ 8xULN)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(ALT&gt;8x - ≤ 20xULN) or (AST&gt;8x - ≤ 20xULN)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ALT&gt;20xULN or AST&gt; 20 xULN</td>
<td></td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>&gt;ULN - ≤1.5xULN</td>
<td>FDA DILI Guidance Jul 2009.</td>
</tr>
<tr>
<td></td>
<td>&gt;1.5 – ≤2.5 xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;2.5 – ≤5.0 x ULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;5.0 – ≤20.0 x ULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;20.0 x ULN</td>
<td></td>
</tr>
<tr>
<td>Total Bilirubin</td>
<td>&gt;ULN - ≤1.5xULN</td>
<td>FDA DILI Guidance Jul 2009.</td>
</tr>
<tr>
<td></td>
<td>&gt;1.5 – ≤2xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;2 – ≤ 3xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;3 – ≤10xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;10xULN</td>
<td></td>
</tr>
<tr>
<td>Direct Bilirubin</td>
<td>&gt;ULN - ≤1.5xULN</td>
<td>FDA DILI Guidance Jul 2009.</td>
</tr>
<tr>
<td></td>
<td>&gt;1.5 – ≤2xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;2 – ≤ 3xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;3 – ≤10xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;10xULN</td>
<td></td>
</tr>
<tr>
<td>ALT and Total Bilirubin</td>
<td>ALT&gt;3xULN and TBILI&gt;2xULN</td>
<td>FDA DILI Guidance Jul 2009.</td>
</tr>
<tr>
<td>AST and Total Bilirubin</td>
<td>AST&gt;3xULN and TBILI&gt;2xULN</td>
<td>FDA DILI Guidance Jul 2009.</td>
</tr>
<tr>
<td>(ALT or AST) and Total Bilirubin</td>
<td>(ALT&gt;3xULN or AST&gt;3xULN) and TBILI&gt;2×ULN</td>
<td>FDA DILI Guidance Jul 2009.</td>
</tr>
</tbody>
</table>
### Table 12-3  Threshold Analysis Criteria for Laboratory Tests (as applicable)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Threshold Analysis</th>
<th>Comments</th>
</tr>
</thead>
</table>
| GGT                  | >ULN - ≤ 2.5xULN  
>2.5 – ≤ 5.0xULN  
>5.0 – ≤ 20.0xULN  
>20.0xULN                | CTCAE grade 1-4                   |
| **Clinical Chemistry (NON-LFT)** |                                                                                      |                   |
| Albumin              | <LLN - ≥ 30 g/L  
<30 – ≥ 20 g/L  
<20 g/L            | CTCAE grade 1-3                   |
| Amylase              | >1x - ≤ 1.5xULN  
>1.5x - ≤ 2xULN  
>2x - ≤ 5xULN  
>5xULN                | Criteria based upon CTCAE          |
| Creatinine           | >ULN - ≤ 1.5xULN  
>1.5 - ≤ 3.0xULN  
>3.0 - ≤ 6.0xULN  
>6.0xULN            | CTCAE grades 1-4                   |
| Lipase               | >ULN - ≤ 1.5xULN  
>1.5x - ≤ 2xULN  
>2x - ≤ 5xULN  
>5xULN                | Criteria based upon CTCAE          |
| Total protein        | <LLN                                                                   | No CTCAE           |
|                     | >ULN                                                                   |                   |
| Creatine kinase      | >ULN - ≤ 2.5 x ULN  
>2.5 - ≤ 5 x ULN  
>5 - ≤ 10x ULN  
>10 x ULN            | CTCAE grades 1-4                   |
| **Hematology**       |                                                                                      |                   |
| Hemoglobin           | Hgb decreased (anemia)  
<LLN - ≥ 100 g/L  
<100 – ≥ 80 g/L  
< 80 g/L            | CTCAE grade 1-3                   |
|                      | Hgb increased  
>ULN - ≤ 20 g/L above ULN  
>20 g/L above ULN - ≤ 40 g/L above ULN  
>40 g/L above ULN      |                   |
| Platelets            |                                                                                      |                   |
|                     | Platelet decreased  
<LLN - ≥ 75.0 x 10e9 /L  
<75.0 – ≥ 50.0 x 10e9 /L  
<50.0 – ≥ 25.0 x 10e9 /L  
<25.0 x 10e9 /L            | CTCAE grade 1-4                   |
|                      | Platelet increased  
>ULN                                                                 | No CTCAE available    |
### Table 12-3  Threshold Analysis Criteria for Laboratory Tests (as applicable)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Threshold Analysis</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reticulocytes/Erythrocytes (%)</td>
<td>&lt;LLN</td>
<td>No CTCAE</td>
</tr>
<tr>
<td></td>
<td>&gt;ULN</td>
<td></td>
</tr>
<tr>
<td>Coagulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activated partial thromboplastin time</td>
<td>&gt;ULN - ≤ 1.5 x ULN</td>
<td>CTCAE grade 1-3</td>
</tr>
<tr>
<td>(PTT)</td>
<td>&gt;1.5 – ≤ 2.5 x ULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;2.5 x ULN</td>
<td></td>
</tr>
<tr>
<td>Prothrombin time (PT)</td>
<td>&gt;ULN - ≤ 1.5 x ULN</td>
<td>CTCAE grade 1-3</td>
</tr>
<tr>
<td>International</td>
<td>&gt;1.5 – ≤ 2.5 x ULN</td>
<td></td>
</tr>
<tr>
<td>Normalized Ratio (INR)</td>
<td>&gt;2.5 x ULN</td>
<td></td>
</tr>
</tbody>
</table>

### Table 12-4  Threshold Analysis Criteria for ECGs

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Threshold Analysis</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR</td>
<td>Bradycardia</td>
<td>Per HV grade 2, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>&lt;50 bpm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;45 bpm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decrease from baseline ≥10 bpm</td>
<td>Per HV grade 2, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>Decrease from baseline ≥20 bpm</td>
<td>Per HV grade 2, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>&lt;50 bpm and decrease from baseline ≥10 bpm</td>
<td>Per HV grade 2, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>&lt;50 bpm and decrease from baseline ≥20 bpm</td>
<td>Per HV grade 2, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>Tachycardia</td>
<td>Per HV grade 1, 2, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>&gt;100 bpm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;115 bpm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;130 bpm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase from baseline ≥10 bpm</td>
<td>Per HV grade 1, 2, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>Increase from baseline ≥20 bpm</td>
<td>Per HV grade 1, 2, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>&gt;100 bpm and increase from baseline ≥10 bpm</td>
<td>Per HV grade 1, 2, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>&gt;100 bpm and increase from baseline ≥20 bpm</td>
<td>Per HV grade 1, 2, 3, plus shift change</td>
</tr>
<tr>
<td>PR</td>
<td>≥240 ms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥300 ms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥200 ms and increase from baseline ≥40 ms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥200 ms and increase from baseline ≥100 ms</td>
<td></td>
</tr>
<tr>
<td>QRS</td>
<td>&gt;110 ms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;160 ms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase from baseline ≥20 ms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase from baseline ≥40 ms</td>
<td></td>
</tr>
</tbody>
</table>
Table 12-4  Threshold Analysis Criteria for ECGs

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Threshold Analysis</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>QTc</td>
<td>&gt;450 to &lt;500ms (Male) or &gt;470 to &lt;500ms (Female) ≥500 ms</td>
<td>Increase from baseline Increase from baseline &gt;10 ms Increase from baseline &gt;20 ms Increase from baseline &gt;40 ms Increase from baseline &gt;60 ms To be applied to any kind of QT correction formula.</td>
</tr>
</tbody>
</table>

Table 12-5  Threshold Analysis Criteria for Vital Signs

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Threshold Analysis</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulse Rate</td>
<td>Same as above in ECG category</td>
<td>809/770 analyses</td>
</tr>
<tr>
<td>SBP increased</td>
<td>&gt;140 mmHg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;160 mmHg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;10 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;20 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;140 mmHg &amp; &gt;10 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;140 mmHg &amp; &gt;20 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;160 mmHg &amp; &gt;10 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;160 mmHg &amp; &gt;20 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td>SBP decrease</td>
<td>&lt;90 mmHg</td>
<td>Per HV grade 1, 3, plus shift change</td>
</tr>
<tr>
<td></td>
<td>&lt;80 mmHg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;10 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;20 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;90 mmHg and &gt;10 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;90 mmHg and &gt;20 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;80 mmHg and &gt;10 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;80 mmHg and &gt;20 mmHg decrease from baseline</td>
<td></td>
</tr>
</tbody>
</table>
### Table 12-5  Threshold Analysis Criteria for Vital Signs

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Threshold Analysis</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>DBP increased</td>
<td>&gt;90 mmHg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;100 mmHg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;5 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;10 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;90 mmHg and &gt;5 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;90 mmHg and &gt;10 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;100 mmHg and &gt;5 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;100 mmHg and &gt;10 mmHg increase from baseline</td>
<td></td>
</tr>
<tr>
<td>DBP decreased</td>
<td>&lt;60 mmHg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;45 mmHg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;5 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;10 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;60 mmHg and &gt;5 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;60 mmHg and &gt;10 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;45 mmHg and &gt;5 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;45 mmHg and &gt;10 mmHg decrease from baseline</td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td>Weight gain</td>
<td>CTCAE grade 1-3</td>
</tr>
<tr>
<td></td>
<td>≥5 % increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥10 % increase from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥20% increase from baseline</td>
<td></td>
</tr>
<tr>
<td>Weight loss</td>
<td>Weight loss</td>
<td>CTCAE grade 1-3</td>
</tr>
<tr>
<td></td>
<td>≥5 % decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥10 % decrease from baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥20% decrease from baseline</td>
<td></td>
</tr>
</tbody>
</table>

### Table 12-6  Threshold Analysis Criteria for Laboratory Tests (for labeling purpose)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Threshold Analysis</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Chemistry (LFT)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT or AST</td>
<td>&gt;3xULN</td>
<td>For labeling purpose</td>
</tr>
<tr>
<td></td>
<td>&gt;5xULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;8xULN</td>
<td></td>
</tr>
</tbody>
</table>
# Appendix G: Adverse Events of Special Interest

## Table 12-7 MedDRA Preferred Terms for Event of Special Interest

<table>
<thead>
<tr>
<th>Adverse event of special interest</th>
<th>MedDRA preferred terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevated transaminase</td>
<td>Alanine aminotransferase abnormal, Alanine aminotransferase increased, Aspartate aminotransferase abnormal, Aspartate aminotransferase increased, Transaminases abnormal, Transaminases increased, Liver function test abnormal, Liver function test increased, Hypertransaminasaemia, Hepatic enzyme abnormal, Hepatic enzyme increased</td>
</tr>
<tr>
<td>Rash</td>
<td>Rash, Rash erythematous, Rash macular, Rash maculo-papular, Rash maculovesicular, Rash vesicular, Rash pruritic, Rash follicular, Rash pustular, Rash generalized, Nodular rash, Drug eruption, Fixed eruption, Generalised erythema, Urticaria, Urticaria popular, Urticaria vesiculosa, Rash morbilliform, Rash popular, Rash papulosquamous, Rash rubelliform, Rash scarlatiniform, Drug hypersensitivity, Type IV hypersensitivity reaction, Dermatitis, Dermatitis atopic, Epidermolysis, Skin toxicity, Dermatitis allergic, Dermatitis exfoliative, Dermatitis exfoliative generalized, Erythema multiforme, Exfoliative rash, Mucocutaneous rash, Acute generalised exanthematous pustulosis, Cutaneous vasculitis, Urticarial vasculitis, Dermatitis bullous, Drug reaction with eosinophilia and systemic symptoms, Epidermal necrosis, Oculomucocutaneous syndrome, Skin exfoliation, Skin necrosis, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Toxic skin eruption, Perioral dermatitis, Vasculitic rash</td>
</tr>
</tbody>
</table>

Note: The preferred terms listed in the table are based on the MedDRA version applicable at the time of the finalisation of the SAP. If the MedDRA version is upgraded at the time of the analysis, the corresponding preferred terms based on the upgraded version will be used in the analysis of adverse events of special interest.